BACKGROUND/AIMS: Mouse models are an essential experimental tool for investigating the role of molecular mechanisms and genetic susceptibility in the development of diabetic nephropathy. METHODS: The most widely used inbred strain, the C57BL/6 mouse, is commonly used in streptozotocin-induced models of type 1 diabetes and is particularly susceptible to obesity-induced type 2 diabetes. However, use of this strain has been criticised by studies suggesting that it is relatively resistant to renal injury. RESULTS: Recent refinement of these models and utilisation of genetically modified (knockout and transgenic) mice on a C57BL/6 background has provided important insights into the roles of oxidative stress, advanced glycation end products, inflammation and profibrotic mechanisms in the development of type 1 and type 2 diabetic nephropathy. CONCLUSION: These findings demonstrate the utility of mouse models for identifying and testing novel therapeutic strategies which could translate into better protection against the human disease. Copyright 2006 S. Karger AG, Basel.
BACKGROUND/AIMS: Mouse models are an essential experimental tool for investigating the role of molecular mechanisms and genetic susceptibility in the development of diabetic nephropathy. METHODS: The most widely used inbred strain, the C57BL/6 mouse, is commonly used in streptozotocin-induced models of type 1 diabetes and is particularly susceptible to obesity-induced type 2 diabetes. However, use of this strain has been criticised by studies suggesting that it is relatively resistant to renal injury. RESULTS: Recent refinement of these models and utilisation of genetically modified (knockout and transgenic) mice on a C57BL/6 background has provided important insights into the roles of oxidative stress, advanced glycation end products, inflammation and profibrotic mechanisms in the development of type 1 and type 2 diabetic nephropathy. CONCLUSION: These findings demonstrate the utility of mouse models for identifying and testing novel therapeutic strategies which could translate into better protection against the human disease. Copyright 2006 S. Karger AG, Basel.
Authors: Kelly L Hudkins; Warangkana Pichaiwong; Tomasz Wietecha; Jolanta Kowalewska; Miriam C Banas; Min W Spencer; Anja Mühlfeld; Mariko Koelling; Jeffrey W Pippin; Stuart J Shankland; Bardia Askari; Mary E Rabaglia; Mark P Keller; Alan D Attie; Charles E Alpers Journal: J Am Soc Nephrol Date: 2010-07-15 Impact factor: 10.121
Authors: Daniela M Schlatzer; Jean-Eudes Dazard; Moyez Dharsee; Rob M Ewing; Serguei Ilchenko; Ian Stewart; George Christ; Mark R Chance Journal: Mol Cell Proteomics Date: 2009-06-04 Impact factor: 5.911
Authors: Gavasker A Sivaskandarajah; Marie Jeansson; Yoshiro Maezawa; Vera Eremina; Hans J Baelde; Susan E Quaggin Journal: Diabetes Date: 2012-11 Impact factor: 9.461